IBD Program
Ulcerative colitis and Crohn's disease
PreclinicalActive
Key Facts
Indication
Ulcerative colitis and Crohn's disease
Phase
Preclinical
Status
Active
Company
About Orphagen Pharmaceuticals
Orphagen Pharmaceuticals, founded in 2001 and based in San Diego, is a private, preclinical-stage biotech focused on drug discovery for orphan nuclear receptors. The company has built a platform for screening ligands to modulate these receptors, leading to a pipeline with programs in oncology (including adrenal and squamous cancers) and inflammatory bowel disease (ulcerative colitis and Crohn's disease). As a pre-revenue entity, Orphagen's strategy involves internal R&D to generate first-in-class drug candidates for subsequent partnership or clinical development.
View full company profileTherapeutic Areas
Other Ulcerative colitis and Crohn's disease Drugs
| Drug | Company | Phase |
|---|---|---|
| ExoFlo™ | Direct Biologics | Phase 1 |